<DOC>
	<DOC>NCT00666276</DOC>
	<brief_summary>Drug use investigation of Zyvox for patients with Methicillin-resistant Staphylococcus aureus (MRSA) infection disease. The objective of this surveillance is to collect information about 1) adverse drug reaction not expected from the Package Insert (unknown adverse drug reaction), 2) the incidence of adverse drug reactions in this surveillance, and 3)factors considered to affect the safety and/or efficacy of this drug.</brief_summary>
	<brief_title>Drug Use Investigation Of Zyvox (Linezolid) (Regulatory Post Marketing Commitment Plan)</brief_title>
	<detailed_description>All the patients whom an investigator prescribes the first Linezolid should be registered consecutively until the number of subjects reaches target number in order to extract patients enrolled into the investigation at random.</detailed_description>
	<mesh_term>Staphylococcal Infections</mesh_term>
	<mesh_term>Linezolid</mesh_term>
	<criteria>Patients need to be administered Linezolid in order to be enrolled in the surveillance. Patients not administered Linezolid.</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
</DOC>